USA flag logo/image

An Official Website of the United States Government

Commercialization of a Human Myocyte and Adipocyte Co-Culture System

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
85548
Program Year/Program:
2007 / SBIR
Agency Tracking Number:
DK074253
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
ZEN-BIO, INC.
P.O. BOX 13888 3200 CHAPEL HILL-NELSON BLVD. RTP, NC 27709-
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2007
Title: Commercialization of a Human Myocyte and Adipocyte Co-Culture System
Agency: HHS
Contract: 1R43DK074253-01A2
Award Amount: $184,782.00
 

Abstract:

DESCRIPTION (provided by applicant): The well documented rise in obesity over the past two decades correlates with increased incidence rates of metabolic and cardiovascular disease. In response to the associated reduced life expectancy and expensive health problems the NIH has established an Obesity Research Task Force. The product development proposed in this SBIR application directly addresses the needs outlined in the Task Force's August 2004 Strategic Plan. One of the tenets of the plan is supporting re search toward breaking the link between obesity and its related disorders. Increased abdominal adiposity correlates with defects in glucose homeostasis and is associated with decreased insulin sensitivity in peripheral tissue. Skeletal muscle is an importa nt site of insulin-stimulated glucose disposal and is often the site of insulin resistance in obese individuals. To support research in this area, we propose to develop a well characterized, widely commercially available co-culture system of primary human skeletal myocytes and adipocytes. This cell system will allow researchers to investigate the complex interaction between two cell types directly involved in the etiology of Type 2 diabetes and metabolic disease. Zen-Bio has been providing cultured primary human cells commercially to researchers for the past 10 years and has established the expertise required for the completion of this proposal. The focus of the company has been adipocytes, however, scientists at Zen-Bio have expertise in the isolation, expa nsion, and differentiation of many types of human primary cells, including myoblasts. Phase I of this proposal consists of two aims. Aim I is expected to establish robust human satellite cell isolation, culturing, and myoblast differentiation protocols. Ai m II will build on Aim I by optimizing and validating a co-culture system using human adipocytes and human skeletal muscle cells. Aim I will be achieved by systematically modifying existing protocols to suit the needs of a commercial myocyte system. Detail ed activity analysis of each cell type in co-culture conditions will aid in optimizing the system in Aim II. Validation of the interaction between the two cell types in co-culture will be assessed by monitoring skeletal muscle cell insulin signal transduct ion. Phase II of the project consists of three aims. Aim I is to develop the necessary quality control assays for skeletal muscle cells prior to commercialization, Aim II is to develop a suite of skeletal muscle cell based contract assay services suitable for the study of metabolic disease, and Aim III is the establishment of a cell repository containing cultured adipocytes and skeletal muscle cells from the same patient. Multiple product offerings are expected from this proposal: a human skeletal muscle ce ll system, a co-culture system using adipocytes and skeletal muscle cells, contract assay services, and assay kits for skeletal muscle cells. At the completion of this project, a commercially available, fully validated human skeletal myocyte system, skelet al myocyte / adipocyte co-culture system, and related assay kits will be offered to researchers. The availability of these systems will provide opportunities for new approaches in the investigation of metabolic disease and a unique methodology to examine t he complex interaction between these two cell types.

Principal Investigator:

Yolanda R. Leacurrie
9195470692
RENEE@ZEN-BIO.COM

Business Contact:


ben@zen-bio.com
Small Business Information at Submission:

ZEN-BIO, INC.
P.O. BOX 13888 3200 CHAPEL HILL-NELSON BLVD. RTP, NC 27709

EIN/Tax ID: 561940166
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No